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ABSTRACT 
Excitement is a problem when conducting endocrine tests on fractious horses. 
Epinephrine (EPI), for example, was shown to obliterate the insulin-induced decrease in blood 
glucose concentrations. Sedation may be a solution; however, perturbation of results may 
preclude useful information. The objectives of the four experiments presented herein were 1) to 
determine the effects of EPI on insulin response to glucose infusion (IR2G), 2) to assess the 
effects of the α-adrenergic sedative, detomidine (DET), alone or in combination with the opioid 
agonist, butorphanol (BUT), on IR2G and glucose response to insulin (GR2I), and 3) to assess 
the effects of BUT alone on IR2G. In Experiment 1, mares were administered saline or EPI (5 
ug/kg, intravenously) immediately before infusion of glucose (100 mg/kg BW). Glucose caused 
peak rise (P < .05) in plasma insulin in controls at 5 minutes that persisted through 30 minutes; 
insulin was suppressed (P < .05) by EPI from 5 to 15 minutes, rising gradually through 30 
minutes. Experiments 2 (IR2G) and 3 (GR2I) were carried out as separate triplicated 3 x 3 Latin 
square designs with the following treatments: saline (SAL), DET, and the combination of 
DET/BUT, all administered intravenously at .01 mg/kg BW. There was a 6-day washout period 
between phases. Blood samples from indwelling catheters were collected at -10 and 0 minutes 
before treatment, and continued every 5 minutes for 40 minutes. Infusion of glucose occurred 10 
minutes after sedation. Glucose caused an immediate rise (P < .05) in plasma insulin that 
persisted through 30 minutes in SAL mares; DET and DET/BUT severely suppressed (P < 
.0001) the IR2G. To assess the GR2I in Experiment 3, blood glucose was measured after 
treatment with recombinant human insulin (50 mIU/kg BW, intravenously). Sedation did not 
affect resting blood glucose and had inconsistent effects on the GR2I. The administration of 
BUT alone in Experiment 4 had no effect on IR2G. In conclusion, adrenergic agonists severely 
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suppress the IR2G and cannot be used for sedation for this test. The use of DET did not alter the 
GR2I, and therefore may be useful for conducting this test in fractious horses. 
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CHAPTER 1. INTRODUCTION 
The most common form of insulin dysregulation in horses is compensated insulin 
resistance [1,2]. Whatever the cause, the long term resistance of peripheral tissues to insulin 
secreted by the pancreatic beta (β) cells necessitates the hypersecretion of insulin in order to 
maintain normal blood glucose concentrations. Thus, both resting (nonfed, feed deprived, or 
between meals) insulin concentrations as well as postprandial insulin responses are greater in 
resistant horses compared to horses of normal insulin sensitivity [1-5]. Given the complexity of 
the two classical methods of assessing insensitivity in horses (the hyperinsulinemic-euglycemic 
clamp [6,7] and the minimal modeling of the modified glucose tolerance test [8,9]), Caltibilota et 
al [10] developed and tested a simple insulin challenge method based on intravenous injection of 
recombinant human insulin (50 mIU/kg of body weight to start) and glucose measurement with a 
hand held glucometer. In that report, and in several subsequent reports of follow-up research 
[4,11-13], it was demonstrated that this method (hereafter referred to as the GR2I)  produced 
repeatable estimates of insulin sensitivity and could be used in lieu of the two more complex 
methods for assessing effects of various conditions (such as obesity), treatments (such as 
dexamethasone injection), and feeding regimens (e.g., fed versus feed deprived). 
In reports published subsequent to Caltibilota et al [10], the insulin response to glucose 
infusion (hereafter referred to as IR2G) was also assessed [4,13]. Cartmill et al [5] first reported 
that hyperleptinemic horses had exaggerated IR2G. Those hyperleptinemic horses were 
subsequently found to be insulin resistant [14], and it was concluded that the long term 
hyperinsulinemia was driving the hyperleptinemia. The difference between the insulin responses 
of horses selected for insulin resistance and those selected for high insulin sensitivity are very 
revealing: the pre-glucose resting insulin concentrations in plasma are typically twice as high 
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compared to normal horses, and the immediate rise in insulin concentrations after glucose 
infusion (net change in concentrations) also double or triple, depending on the experiment 
[4,11,13].  
On factor known to perturb the assessment of insulin sensitivity by the classical methods 
is excitement. Apparently epinephrine (EPI) from the adrenal glands in spooked or fractious 
horses acts on insulin sensitive tissues and interferes with the action of insulin. In fact, Earl et al 
[11] reported that administration of EPI at 5 ug/kg of body weight (BW) totally obliterated the 
glucose response (decrease) to injected insulin; in fact, blood glucose increased in the face of 
high insulin, apparently due to liver glycogenolysis. Thus, the question that arises is “how does 
one assess insulin sensitivity in a fractious horse?” Sedatives are typically used to perform 
various simple chores on fractious horses; however, their effects on GR2I or IR2G are not 
known.  
Given these facts, the four experiments described herein were conducted to empirically 
determine 1) the effect of EPI pretreatment on the IR2G, as a follow-up to the data of Earl et al 
[11], 2) the effects of two common methods of sedation used in horses [15]; detomidine alone 
versus detomidine plus butorphanol) on the results of the GR2I and the IR2G relative to the 
nonsedated (control) responses, and 3) the effects of BUT alone on IR2G. 
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CHAPTER 2. REVIEW OF LITERATURE 
 
2.1 Insulin secretion 
Insulin is produced within the body by the pancreas, which is a glandular organ that plays 
a vital role in the digestive system as an exocrine organ and an endocrine gland [16] The 
exocrine functions of the pancreas include neutralizing gastric acid to prevent damage to 
duodenal mucosa, and breaking down proteins, fats, and starch in order for their constituents to 
be absorbed through the mucosa into blood. As an endocrine organ, the pancreas’ role is 
primarily carbohydrate and lipid metabolism via the secretion of insulin and glucagon, which aid 
in maintaining normal blood glucose concentrations [16]. 
Within the pancreas, there is a collection of cells clustered into islands, known as the 
Islets of Langerhans [16]. The islets of Langerhans are essential for maintaining normal 
glycemia. The predominant cells (90% by number) within these islets consist of two types, the 
alpha (α) and beta (β) cells. Beta cells release insulin, while α cells release glucagon. Following a 
meal, the hyperglycemia induced postprandially causes islet β-cells to release insulin which 
stimulates insulin-sensitive cells in the body (primarily striated muscle, liver, and fat) to readily 
absorb glucose [17]. When hypoglycermia occurs between meals, the α-cells secrete glucagon, 
the major blood glucose-elevating hormone [17]. Insulin secretion is stimulated when blood 
glucose is higher than necessary, causing cells to take up excess glucose from the blood and 
convert it to stored glycogen and triacylglycerols (fat). Glucagon secretion is stimulated when 
blood glucose is lower than normal, causing tissues, like the liver, to breakdown glycogen to 
produce glucose (glycogenolysis), produce new glucose (gluconeogenesis), and to oxidize fats to 
reduce the need for glucose [18].  
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The β-cells store insulin in secretory vesicles, and in order to release insulin outside the 
cell, calcium must be present, therefore calcium receptors exist on these secretory vesicles [19]. 
Another important component of β-cells is the presence of potassium channels. These potassium 
channels allow K+ to leave the β-cells through facilitated diffusion [20]. When the cell is 
unstimulated, there are more K+ in the extracellular fluid surrounding cells than inside the cells. 
This prevents the β-cells from depolarizing. When glucose concentrations increase inside the β-
cell, K+ levels rise, eventually resulting in a depolarization of the cells [18]. When the β-cell 
membrane depolarizes, calcium channels present in the cell membrane open and allow Ca++ 
ions into the cytoplasm, resulting in vesicle fusion with the cytoplasmic membrane and 
exocytosis of stored insulin [16]. 
2.2 Insulin action 
Once insulin is secreted, it must bind to its specific receptors in target tissues in order to 
transmit its signal [16]. These receptors are known to be members of a larger family of plasma 
membrane receptors that possess inherent protein kinase activity; these are fundamentally 
different than G-protein coupled receptors (later discussed) activity when transmitting its 
extracellular signal [21]. Tyrosine kinases have unique domains that phosphorylate tyrosine 
residues in specific target proteins inside the cell [21]. Insulin does not enter the cell, but instead 
initiates its signal at the plasma membrane level via specific receptors that transmit the signal to 
insulin-sensitive second messenger systems in the cytosol. The insulin receptor contains two α 
subunits and two β subunits. The alpha subunits contain the insulin-binding domain, while the 
beta subunits contain the tyrosine kinase activity that is responsible for transferring a phosphoryl 
group from ATP to the hydroxyl group of the tyrosine residues in the target protein [21]. The 
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action of insulin inside the cell is well described in detail by Krahl [22] and graphically depicted 
in detail by Rhodes [22]. 
2.3 Glucose metabolism 
            Every cell in the body needs energy to survive and perform different functions. Energy is 
needed to stimulate other cells to send signals and messages throughout the body. For example, 
muscle cells need energy to contract and perform basic functions and the primary source of 
energy is glucose [18]. Glucose is an abundant monosaccharide contained in the disaccharides 
and starches of various plants that are consumed by animals. In animals, in order to produce 
glucose, glycogen must be broken down through the process of glycogenolysis [18]. Glucose is 
also synthesized in the liver and kidneys from non-carbohydrate intermediates (i.e. glycerol, 
amino acids, lactate, and propionate) through gluconeogenesis [18].  
Once absorbed or made, glucose is delivered through portal venous blood to many target 
tissues that require energy. When a cell needs energy, glucose is taken up into the cell, which 
must be assisted by the hormone, insulin. Insulin receptors exist on the cell membrane of many 
target tissues, such as skeletal muscle, adipose tissue, and the liver [22]. Insulin must bind to the 
insulin receptors to allow glucose to be taken up by the cell. This process however can be 
disrupted if the body cannot produce insulin (from the pancreas), therefore there won’t be insulin 
to bind to the insulin receptors, and therefore, glucose will not be allowed to enter into the cell. 
This is known as Type I diabetes mellitus in humans [16]. Another disruption that commonly 
occurs is a lack of insulin action in target cells. In this case, there is the presence of insulin, yet 
glucose is not taken into the cell in a normal fashion. This is known as type II diabetes mellitus 
in humans [16]. In addition to a paucity of glucose available for tissue function in type II 
diabetics, there are other dysregulations that can lead to illness and possibly death if untreated, 
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such as kidney disease, hyperglycemia, dyslipidemia, hyperlipidemia, and eventual 
arteriosclerosis [18].  
 2.4 Insulin sensitivity and resistance in horses   
Insulin sensitivity is an interesting phenomenon in horses compared to humans because 
of their ability to withstand higher levels of insulin secretion from pancreatic β cells for longer 
periods of time. Insulin resistance in horses is a metabolic condition, like type II diabetes in 
humans, in which the body’s peripheral tissues show a reduction in insulin sensitivity or inability 
to respond, despite having normal or increased insulin concentrations in the blood [1].    
A main difference between horses and humans relative to insulin resistance is that horses 
can tolerate hyperinsulinemia without experiencing pancreatic exhaustion, which could 
ultimately lead to type I diabetes mellitus in humans [18]. Horses with insulin resistance 
compensate for the reduced action of insulin at the target tissue level by hypersecreting insulin 
virtually 24 hours a day [1], hence the term coined by Kronfeld and others [1,2] “compensated 
insulin resistance” for the type II diabetic situation in horses. Insulin resistant horses display 
resting (basal, feed-restricted, or between meal) blood insulin concentrations about twice those 
observed in normal horses [5,25]. Moreover, the insulin response to a meal or to glucose infusion 
is also greatly exaggerated [4,5,25].  
 The constantly high blood insulin concentrations in resistant horses can cause various 
dysfunctions in other systems in the body. Insulin resistance is involved in, or at least associated 
with, the pathogenesis of equine conditions such as pituitary pars intermedia dysfunction (PPID; 
[25]), equine metabolic syndrome (EMS; [26]), hyperlipidemia, laminitis, endotoxemia, and 
osteochondrosis (reviewed by Firshman and Valberg [27]). Dysregulation of insulin such as 
hyperinsulinemia and a decreased sensitivity to insulin are two major causes of EMS, which is a 
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common endocrinopathy in horses characterized by the persistent high levels of blood glucose 
and subsequent pancreatic exhaustion, upregulation of inflammatory markers, arterial 
hypertension, and reduced glycemic control [30]. It may also cause infertility, hyperleptinemia, 
and hypertriglyceridemia (reviewed by Johnson et al. [30]). Insulin resistance is believed to have 
a genetic component, at least in pony mares [28], but has been shown to be inducible in horses 
by high glycemic diets [1,2,29], dexamethasone administration [31-33], and free fatty acid 
infusion [34]. 
2.5 Methods for testing insulin sensitivity                                                                                                                   
The two classical methods of assessing insensitivity in horses are the hyperinsulinemic-
euglycemic clamp [6,7] and the minimal modeling of the modified glucose tolerance test [8,9]. 
The clamp technique involves infusion of insulin at 1 or more fixed doses (only one per trial) and 
then sufficient glucose to maintain euglycemia [6,7]. The amount of glucose required to 
counteract the given dose of infused insulin indicates the relative glucose sensitivity of the 
subject: sensitive horses uptake more glucose than insensitive horses, hence a greater glucose 
infusion rate is required to establish and maintain euglycemia. The minimal model technique is 
basically a modified glucose tolerance test that involves the rapid infusion of a high dose of 
glucose at time 0, and then very frequent blood sampling to assess the rise and subsequent fall of 
blood glucose concentrations [8,9]. In the modified version, a large dose of insulin is 
administered intravenously at 20 minutes after glucose infusion. For proper application of either 
of these techniques, insulin concentrations must be measured in the laboratory to calculate the 
estimates of insulin sensitivity. The complexity of these techniques and the need for insulin 
measurement preclude them being useful for on-farm use.  
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In 2010, Caltibilota and colleagues [10] at LSU, reported on a simple, on-farm friendly 
alternative to these complicated approaches. Their test involves measuring the glucose response 
in horses to a standard intravenous injection of recombinant human insulin (50 mIU/kg BW). 
Blood glucose concentrations are measured before injection (-10 and 0 minutes) by means of a 
simple hand-held glucometer and then subsequent to insulin injection at 40 and 60 minutes. The 
post-treatment blood glucose concentrations are compared to the pre-injection average, and the 
greatest decrease, relative to pre-injection, is calculated as a percentage of the pre-injection 
average. Horses with normal or high insulin sensitivity will typically have a maximum post-
injection decrease of 50% or greater [10-12]. Insulin resistant horses will display post-injection 
decreases of 0 to 30%. Decreases falling between 30 and 50% are equivocal and would require 
further study. For the most reliable assessment of insulin sensitivity, Caltibilota et al [10] 
suggested that three insulin doses should be tested (the standard of 50 mU/kg BW, plus two 
higher or lower depending on the first response); however, follow-up research showed that the 
response to the standard dose was very predictive of the results for the three-dose regimen [11].  
Although the decrease in blood glucose after a standard injection of insulin (referred to as 
the glucose response to insulin, or GR2I) was very revealing as to a horse’s insulin sensitivity 
status, subsequent research drew upon the fact that horses with compensated insulin resistance 
also consistently display an exaggerated insulin response after a meal or after the infusion of 
glucose [1,2,5]. Thus, subsequent research reports on factors affecting insulin sensitivity utilized 
both GR2I results as well as results from glucose infusion tests (the insulin responses to glucose, 
or IR2G). Combined, the results from these two tests give very reliable estimates of the 
assessment of insulin sensitivity [13,35].  
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 A currently in vogue approach to assessing insulin sensitivity is the oral glucose tolerance 
test [36,37]. The basis of the test is the administration of a glucose solution, or alternatively, 
Karo syrup, into the horse’s mouth, with subsequent blood samples typically taken 90 minutes 
later. Due to the need to have insulin concentrations measured in the blood samples, this test is 
not truly on-farm friendly. Other problems with repeatability of the test have been raised by 
researchers [37,38].  
2.6 Adrenergic receptors  
There are two main types of adrenergic receptors: α and β [39]. These main types are 
further differentiated pharmacologically into α1, α2, and β1, β2, and β3 [39] subtypes. Both the 
α1 and α2 types can in fact be even further differentiated in three sub-subtypes each (α1 A, B, 
and D; and α2 A, B, and C). Differentiations of subtypes and sub-subtypes are based on both the 
agonists and antagonists that bind and cause action through the receptors, and also on the relative 
activity of any given agonist (often epinephrine or norepinephrine). 
Beta-adrenergic receptors are primarily involved in the effects of stimulation of the 
sympathetic nervous system [18]. Actions occurring through activation of β1 receptors increase 
the force or energy of muscular contractions (inotropic effects), increase heart rate, and increased 
blood pressure via vascular constriction [18]. Activation of β2 receptors induces smooth muscle 
relaxation in the lungs, gastrointestinal tract, uterus, and various blood vessels [18], as well as 
vasodilation within cardiac muscle. Beta-3-adrenergic receptors are primarily found on adipose 
tissue and are involved with fat metabolism and release [18]. 
Alpha-2-adrenergic receptors (“adrenoceptors”) have been localized both presynaptically 
and postsynaptically [40]. Alpha-2-adrenoceptors have been identified within hypothalamic areas 
such as the periventricular nucleus and supraoptic nucleus, in which these receptors influence 
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food intake [41]. Within adipocytes, α2-adrenoceptors modulate antilipolytic effects [42]. The 
activation of both α- and β-adrenoceptors mediates the sympathoadrenal system and have 
important functions in regulating blood glucose and insulin secretion [43]. Fagerholm et al. [44] 
studied α2 regulation of blood glucose and discovered that receptors can be found on 
sympathetic nerves and adrenomedullary chromaffin cells where their activation limits 
sympathoadrenal output. Within the β cells of the islets, activation of α2-adrenoceptors leads to 
hypoinsulinemia and hyperglycemia [45-47].  
Alpha-2-adrenoceptors have been reported to be integrally involved in the control of 
insulin and glucose. An increase in expression of α2A receptor gene activity has been associated 
with a decrease in the insulin response to an injection of glucose, increase in fasted blood 
glucose, and an increase in the risk of type II diabetes mellitus [44]. This inhibitory effect on 
insulin from adrenoceptor agonists is not related to vasoconstriction [48], but rather the 
prevention of cAMP generation from a decrease in adenylate cyclase activation [42,49].  
2.7 G-protein coupled receptors   
All types and subtypes of adrenoceptors are members of a larger class of membrane 
receptors called G-protein coupled receptors (GPCR; [39]). This is a large and diverse family of 
cell surface receptors that respond to many external signals [21], are only found in eukaryotes, 
and represent the largest class of membrane receptors [50]. An essential and unique characteristic 
of GPCR is their 7-transmembrane α helices [21]. The G-protein coupled receptors combine with 
heterotrimeric G-proteins that bind both guanosine triphosphate (GTP) and guanosine 
diphosphate (GDP). Each G-protein has three subunits; α, β, and γ, that are held to the cell 
membrane via lipid anchors [51]. Detailed graphics showing how GPCR are involved with 
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various responses inside the cell are presented in Dorsam and Gutkind [51] as well as in 
Neumann et al [52]. 
2.8 Detomidine, an 2-agonist 
 Detomidine is a sedative analgesic used to quiet animals for veterinary procedures [53] 
and is widely used in the horse for standing chemical restraint that produces effects centrally 
[15]. Common effects observed using detomidine in the horse are lowering of the head, lower lip 
drooping, slight eye closure, occasional muscle twitches, slight head jerks, leaning on barn walls 
or doors for stability and support, diuresis, and ataxia. The degree of ataxia from detomidine has 
been discovered to be dose-dependent: the higher the dose the more severe the effects for a short 
time [53]. Detomidine has also been reported to cause hypothermia, mydriasis, and hypotension 
[40]. 
Detomidine analgesia is believed to result from the interaction of the agonist with 2-
adrenoceptors located presynaptically on afferents and 2-adrenoceptors located postsynaptically 
on projection neurons [54]. On these projection neurons, the agonists increase K+ flow through 
inhibitory G-coupled potassium channels, thereby causing the cell to hyperpolarize [54]. The 
sedative effect of agonists is also dose-dependent at supraspinal sites, in which the agonists are 
believed to act in a similar manner as the analgesic response, mediated through postsynaptic 2-
adrenoceptors and inhibitory G proteins [54].   
2.9 Butorphanol, an opioid agonist 
Opioids are commonly used in the veterinary world to treat acute and chronic pain. In 
order to improve and hasten the patient’s recovery, it is important to find a balance between 
sedative drugs that bind to different targets in different locations, or by different pain pathway 
mechanisms. This helps to improve the analgesic effect, reduces adverse side effects, and 
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reduces costs [55]. This balance is important when opioids are often used as adjuncts with α2-
agonists during procedures. This multimodal approach enables veterinarians to use smaller 
doses, therefore reducing the side effects. Combining opioids with α2-agonists can reduce and 
abolish a horse’s response to specific stimuli, permitting veterinarians and clinicians to perform 
certain diagnostic and therapeutic procedures [55].  
 Butorphanol (commercially available as the tartrate salt, Torbugesic, Zoetis US, 
Parsippany, NJ) is a short acting (3 to 4 hours when administered intravenously) synthetic 
narcotic analgesic, which acts centrally and must be administered by or on the order of a licensed 
veterinarian [56]. Butorphanol has been approved for use in the horse in the United States, and 
can be administered IV, IM, and SC. It is 4-30 times more potent than morphine and pentazocine 
in animals. Some common side effects include respiratory depression and gastrointestinal stasis 
[55]. When comparing the analgesic contribution between opioids and α2-agonists, α2-agonists 
alone have been found to provide more analgesia and significantly more sedation; opioids 
contribute little to the effects seen by the combination of opioid and α2-agonist [57,58]. Jochle et 
al. [57] studied horses presenting with abdominal pain and compared the effects of detomidine or 
butorphanol (among other sedative agents) and found that detomidine (at 20 or 40 ug/kg BW) 
caused a bigger depression of pulse rate and respiratory rate than butorphanol (.1 mg/kg BW). 
There were also significant differences in clinical signs between butorphanol and either dose of 
detomidine, such as sweating, kicking, pawing, head and body movement, attitude, pulse rate, 
and respiratory rate [57]. Another study [59] found that when comparing detomidine in 
combination with other opioids, detomidine and butorphanol produced the most reliable response 
to sedation (compared to other opioids: morphine, methadone, pethidine). 
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2.10 Epinephrine 
 Epinephrine (EPI), sometimes referred to as adrenaline, is a naturally occurring 
catecholamine and neurotransmitter of the sympathetic nervous system found in the body [18]. 
Epinephrine has both α- and β-adrenergic activities, although it has a higher affinity for the β-
adrenergic receptors than the α-adrenoceptors [21]. Within the sympathetic nervous system, EPI 
is the neurotransmitter found in postsynaptic, sympathetic efferents, and is also produced and 
secreted directly into the blood from the adrenal medulla [18]. When faced with a fight-or-flight 
situation, sympathetic mass discharge results in activation of both systems resulting in the 
characteristic increase in heart rate, constriction of peripheral blood vessels, increased respiratory 
rate, and often subsequent perspiration [18]. Other actions of EPI in the body include increased 
blood glucose concentration due to muscle and liver glycogenolysis, increased energy-yielding 
metabolism in muscle, liver, and adipose tissue, and muscle quiver [21].  
 Epinephrine administration has been used to assess various systems within animal 
research, including glucose metabolism [60-63] and lipid metabolism [64-66]. Exogenous EPI 
increases blood glucose concentrations via increased liver and muscle glycogenolysis [18] and 
also stimulates blood nonesterified fatty acid concentration via increased activity of hormone 
sensitive lipase on adipose tissue [18]. Altered release of glucose or fatty acids in response to 
EPI may reveal metabolic alterations in the body that would not be noticeable otherwise [60-66]. 
Clinicians applying the hyperinsulinemic-euglycemic clamp and the minimal model 
technique have known for years that subjects must remain calm, and that excitement during 
testing will invalidate the test results. The endogenous release of epinephrine following stress 
results in impaired glucose tolerance due to epinephrine suppressing insulin secretion [67]. Earl 
et al [11] showed that EPI administration before a GR2I test totally obliterated the normal 
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insulin-induced decease in blood glucose concentrations, and in fact, concentrations actually 
increased due to glucose mobilization. Epinephrine has also been shown to inhibit the glucose-
stimulated insulin release in other species like the rat [68], however this has not yet been 
reported for the horse. 
2.11 Rationale for present experiments 
            Endocrine diseases like PPID, EMS, and insulin dysregulation are difficult diseases to 
recognize and diagnose. Researchers have shown that two important tests to evaluate these 
disorders relating to insulin and glucose metabolism are the IR2G and GR2I. However, in order 
to evaluate these responses, horses need to be calm; therefore, fractious horses can be a problem 
when performing these tests. Standing chemical restraint in horses is a common practice used to 
avoid complications associated with excited or unruly horses. The drug combination used herein 
(an α2-adrenergic agonist in combination with an opioid) was suggested as a commonly used 
protocol for providing sedation and analgesia in horses.  
Given these facts, the four experiments described herein were conducted to empirically 
determine 1) the effect of EPI pretreatment on the IR2G, as a follow-up to the data of Earl et al 
[11], 2) the effects of two common methods of sedation used in horses ([15]; detomidine alone 
versus detomidine plus butorphanol) on the results of the GR2I and the IR2G relative to the 
unsedated (control) responses, and 3) the effects of BUT alone on IR2G. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 Experiment 1. Epinephrine effects on IR2G 
The LSU AgCenter Institutional Animal Care and Use Committee approved the 
procedures used in this and the subsequent two experiments. Ten light horse mares (primarily 
Quarter horse and thoroughbreds) housed at the LSU AgCenter Central Station horse unit 
previously assessed as insulin sensitive [10] were used. They ranged in age from 3 to 12 years, 
weighed between 385 and 519 kg, and had body condition scores (BCS; Henneke et al [69]) 
between 4.5 and 7. Mares were maintained outdoors on native grass pasture for the duration of 
the experiment. This experiment was performed in June of 2018. 
The experiment was performed as a completely random design with a single switchback. 
That is, on the first day of treatment, five mares were treated with EPI prior to infusion of 
glucose, and five mares received saline prior to glucose infusion. After a week of rest (no 
treatments), the experiment was repeated with the treatment groups reversed. 
In the evening before each treatment day, mares were brought in from pasture and housed 
in stalls in a barn overnight with free access to water but no feed. The next morning at 
approximately 0700 each mare was fitted with a 14-gauge indwelling jugular, which was affixed 
in place with cyanoacrylate glue. A .05% sodium citrate solution was used to keep the catheter 
patent. Once all catheters were in place, the mares were left unperturbed for 1 hour.  
After the hour of rest, blood samples were drawn at -10 and 0 minutes relative to 
treatment. Mares receiving EPI were injected through the catheter with 5 µg/kg BW of EPI (as a 
1 mg/mL solution; Sigma Chem. Co., St. Louis, MO) in saline. Five control mares received 
saline at .005 mL/kg BW.  Within 30 seconds after the first injection, each mare was infused 
with glucose (100 mg/kg BW as a 50% solution; Durvet Inc., Blue Springs, MO) through the 
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jugular catheter. Infusion took about 1 minute to complete. Blood samples were collected at 5, 
10, 15, 20, 25, and 30 minutes relative to onset of glucose infusion. Blood samples were placed 
into 6-mL evacuated plastic tube containing K3EDTA (Vacuette, Greiner Bio-One, Monroe, NC, 
USA). All samples were placed immediately in an ice bath until centrifugation at 1200 x g for 15 
minutes at 5°C. Plasma was harvested and stored at -20°C. 
Once all blood samples had been collected on the first day, the mares were returned to 
pasture until the following treatment day one week later. Procedures from the first treatment day 
were followed on the second treatment day, except the treatments were reversed. 
All plasma samples were analyzed for insulin by immunoradiometric assay (Immuno-
Biological Laboratories, Inc., Minneapolis, MN). Lower limit of detection of the insulin assay 
was < 1 mIU/L. All samples were estimated in one assay; intra-assay coefficient of variation was 
8.8%. 
Insulin data were analyzed in an analysis of variance (ANOVA) with the General Linear 
Model procedure of SAS software (SAS Inst., Cary NC) in a replicated Latin square (5 replicates 
of a 2 x 2 Latin square; Steel et al [70]); square was ignored in the analysis because mares were 
not paired per se and all were treated at the same time. The repetitive nature of the sampling was 
accounted for by use of a split-plot design [70]. Post analysis mean separation was performed 
across time periods with the SLICE command of SAS. 
3.2  Experiment 2. Detomidine and butorphanol effects on the IR2G 
 This experiment was conducted from October 22 through November 5, 2018. Mares of 
light horse types were used. They ranged in age from 5 to 22 years, weighed between 427 and 
528 kg, and had BCS between 5 and 8. Mares were maintained outdoors on native grass pasture 
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for the duration of the experiment. Alicia Bermuda grass hay was supplemented when pasture 
grasses diminished in quantity and quality.  
The experiment was designed as a triplicated 3 x 3 Latin square design with 9 mares. On 
the second day of treatment, one mare was discovered to be totally intractable; it was obvious 
that she would not be able to continue in the experiment and was dropped. The remaining mares 
were allotted to three treatment groups with three mares per group (except for one), and each 
mare received each treatment over the three days of treatment. The treatments consisted of saline 
(SAL, .01 mL/kg BW), detomidine alone (DET, .01 mg/kg BW, Dormosedan, Zoetis, 
Parsippany, NJ), or a combination of detomidine and butorphanol (DET/BUT, .01 mg/kg 
detomidine plus .01 mg/kg BW butorphanol; Torbugesic, Zoetis, Parsippany, NJ). All treatments 
were administered intravenously. A 6-day “washout” period between the three treatment days 
was used to prevent any effects of one treatment from altering the subsequent treatment 
response(s).  
The night before each treatment day, mares were brought in from pasture and were feed-
deprived overnight in stalls; water was available at all times. In the morning (0530), a 14-gauge 
catheter was aseptically placed into the left jugular vein. One hour of rest (inactivity) was 
allowed for acclimation to avoid any stress-associated artifacts. At the start of the experiment, 
baseline blood samples (5-mL) were collected via the catheter at -10 and 0 minutes relative to 
treatment (SAL, DET, or DET/BUT). Once the treatments had been administered, blood was 
again collected at 5 and 10 minutes post-injection to assess immediate treatment effects.  
Following the 10-minute sample post-treatment, a standard dose of glucose (100 mg/kg 
BW, 50% aqueous solution; Durvet) was administered through the jugular catheter over 
approximately a 1-minute period. Subsequent blood samples were collected at 15, 20, 25, 30, 35, 
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40, and 45 minutes relative to the original treatments (5, 10, 15, 20, 25, 30, and 35 minutes 
relative to onset of glucose infusion). Blood samples were processed and stored as described for 
Experiment 1. 
After recovery from treatments, mares were returned to pasture until the next treatment 
day (one week later). Once all plasma samples from the three treatment days had been collected, 
the samples were analyzed for insulin as described in Experiment 1. Insulin data were analyzed 
by ANOVA with SAS software for a triplicated 3 x 3 Latin square [70] with repeated measures. 
Factors in the analysis included square, horse within square, day, treatment, and time (minutes). 
The interaction of treatment and time was also assessed, and any differences among treatment 
groups for specific times were tested via the SLICE option in SAS. 
3.3  Experiment 3. Detomidine and butorphanol effects on the GR2I 
This experiment was basically a repetition of Experiment 2 except that the effects of 
treatment were assessed for the GR2I. It was performed between November 12 and 26, 2018. 
The general procedures regarding the schedule of events on treatment days followed in 
Experiment 2 were repeated. The same mares were used, although a different day-treatment grid 
was used for the assignment of treatment sequences. 
On treatment days, mares were loosely tethered at approximately 0700 in stalls in a barn 
and two samples of jugular blood were collected 10 minutes apart using a tuberculin syringe 
fitted with a 21-gauge, 1-inch long needle (-10 and 0 minutes samples). Blood glucose 
concentrations were assessed in each sample (and all subsequent samples) immediately after 
withdrawal using a hand held glucometer (OneTouch UltraMini, LifeScan, Inc., Milpitas, CA). If 
blood glucose concentrations agreed to within 10% for the two samples, the mare was 
administered its respective treatment. If the samples varied more than 10%, subsequent samples 
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were drawn to establish a constant baseline before proceeding. Treatments were then 
administered intravenously as described for Experiment 2. 
A 5- and 10-minute post-treatment blood sample was collected before insulin was 
injected to assess any effects on basal blood glucose concentrations. Subsequently, recombinant 
human insulin (Sigma) in sterile saline was administered intravenously into the left jugular vein 
at 50 mIU/kg BW. Blood samples were then collected at 40 and 60 minutes after insulin 
injection and were assessed for blood glucose concentration. After recovery from treatments, 
mares were returned to pasture until the next treatment day (one week later). 
Once all blood glucose concentrations had been obtained from the three treatment days, 
the percent decreases in blood glucose concentrations from the pre-insulin concentration (the 10 
minute post-treatment sample) were calculated for the 40 and 60 minute samples [10]; the largest 
decrease of the two estimates was used as the maximum percent decrease for that mare on that 
day. Endpoints calculated from the raw blood glucose concentrations included mean pre-
treatment average (mean of the -10 and 0 minute samples), mean post-treatment concentration 
(the sample collected 10 minutes after treatments were administered), net change in blood 
glucose due to treatment (the post-treatment sample minus the pre-treatment average), and the 
maximum decrease in blood glucose after insulin injection. 
Data from Experiment 3 were analyzed by ANOVA with SAS software for a triplicated 3 
x 3 Latin square [70]. Differences among treatment groups were tested via the PDIFF option in 
SAS with Dunnett adjustment (each treatment versus the control). 
3.4  Experiment 4. Butorphanol effect on IR2G 
Given the effects of DET and DET/BUT on IR2G in Experiment 2, the effect of BUT 
alone was assessed in Experiment 4. Eight light horse mares were used in a single switchback 
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design conducted during February, 2019. Three of the 8 mares had been used in Experiments 2 
and 3. All mares were housed maintained as described for those previous experiments. 
On the first treatment day, four mares selected at random were administered SAL (.01 
mL/kg BW) and four were administered BUT (.01 mg/kg BW) intravenously. On the second 
treatment day, the treatment assignments were reversed. Pre- and post-treatment blood sampling 
times were identical to those in Experiment 1, as was the protocol for infusion of glucose, blood 
sample processing, insulin measurement, and statistical analysis. 
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CHAPTER 4. RESULTS 
4.1  Experiment 1. Epinephrine effect on IR2G 
Mean responses of plasma insulin concentrations to glucose infusion following saline 
versus EPI pretreatment are presented in Figure 4.1. Glucose infusion resulted in an immediate 
rise (P < .05) in plasma insulin concentrations when mares received SAL; this increase persisted 
through 30 minutes after infusion. A treatment by time interaction in the ANOVA (P < .05) was 
observed for insulin concentrations, which were suppressed (P < .05) by EPI at 5 minutes, but 
then gradually increased through the 30-minute sampling period to equal those in mares 
administered SAL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Mean plasma insulin concentrations in mares when injected with SAL 
(Control) or epinephrine (EPI; 5 µg/kg BW) just prior to i.v. infusion of glucose (Glu; 100 mg/kg 
BW) at time 0. Differences between groups for specified time periods are indicated by asterisks 
(*; P < 0.05) or a plus sign (+; P < .10). The pooled SEM was 7.9 mIU/L. 
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4.2  Experiment 2. Detomidine and butorphanol effects on the IR2G 
In order to better evaluate the effects of treatment on plasma insulin concentrations 
before glucose infusion as opposed to after glucose infusion, two separate analyses were 
performed. Analysis of the data from -10 minutes through 10 minutes after SAL, DET, or 
DET/BUT administration revealed that treatment affected resting insulin concentrations (Figure 
4.2; all means are presented). Mean insulin concentration was reduced (P < .05) from 
approximately 8.5 mIU/L at time 0 in all mares to 5.1 mIU/L in the DET and DET/BUT treated 
mares (versus 8.7 mIU/L in SAL mares) 10 minutes later. Once glucose was administered,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Mean plasma insulin concentrations in mares treated (Trt) with SAL, DET, or 
DET/BUT at time 0 prior to i.v. infusion of glucose (Glu; 100 mg/kg BW) 10 minutes later. 
Treatment (DET) and (DET/BUT) suppressed (P < .05) insulin concentrations before (at 10 
minutes) and at all times after glucose administration compared to control (SAL). Pooled SEM 
was 1.2 mIU/L for the first analysis (-10 through 10 minutes) and 5.2 mIU/L for the second 
analysis (15 through 45 minutes).  
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insulin concentrations increased (P < .01) in mares administered SAL, but remained suppressed 
(P < .01) in mares administered DET or DET/BUT (Fig. 2) through the last blood sample 
collected that day. 
4.3  Experiment 3.  Detomidine and butorphanol effects on the GR2I 
 Summaries of data collected from the GR2I challenges are presented in Table 4.1. Before 
any treatments were initiated (sampling times -10 and 0 minutes), mean blood glucose 
concentrations were equivalent across the three treatment groups. At 10 minutes after the SAL, 
DET, and DET/BUT treatments were administered, mean blood glucose concentrations were 
again equivalent across the three treatment groups, which was confirmed by the lack of  
 
Table 4.1. Glucose characteristics before and after treatment and after injection of 
recombinant human insulin in mares in Experiment 3. 
 
Treatmenta Mean pre-
treatment blood 
glucose (mg/dL)b 
Mean 10-min blood 
glucose (mg/dL) 
Δ Glucose after 
treatment 
(mg/dL)c 
Maximum 
decrease in blood 
glucose (%)d 
SAL 101.9 101.9 0 34.8 
DET 104.3 101.4 -2.8 25.4 
DET/BUT 100.9 99.7 -1.2 35.0 
SEMe 1.7 2.7 2.7 4.8 
P-valuef 0.20 0.76 0.51 0.11 
aTreatments were saline (SAL; 0.01 mL/kg BW), detomidine (DET; 0.01 mg/kg BW), and DET 
plus butorphanol (DET/BUT; 0.01 mg/kg BW each). 
bMean of the -10 and 0 minute time samples. 
cMean net difference between the 10 minute sample and the mean pre-treatment average. 
dLargest decrease in blood glucose from time 10 minute sample at either 40 or 60 minutes after 
insulin injection. 
eStandard error of the means. 
fP-value for the treatment effect in the ANOVA. 
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differences in the net change in concentrations from pretreatment to 10 minutes after treatment 
(Δ glucose, Table 4.1). Finally, the maximum percent decrease in blood glucose concentrations 
after insulin injection was not affected overall by treatment (P = .11), although the PDIFF 
procedure indicated that the response after DET sedation tended (P = .08) to be lower than after 
SAL treatment. 
4.4  Experiment 4. Butorphanol effect on IR2G 
 Mean plasma insulin concentrations before and after BUT treatment and following 
glucose infusion are presented in Fig. 4.3. Administration of BUT had no effect (P > .1) on 
resting insulin concentrations (from 0 to +10 minutes); nor did BUT administration alter the 
glucose-induced rise (P < .001) in insulin concentrations over time. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Mean plasma insulin concentrations in mares treated (Trt) with SAL or BUT 
at time 0 prior to intravenous infusion of glucose (Glu; 100 mg/kg BW) 10 minutes later. 
Treatment had no effect on insulin concentrations before (at 10 minutes) or at any time after 
glucose administration compared to control (SAL). Pooled SEM was 1.7 mIU/L.  
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CHAPTER 5.  DISCUSSION 
5.1  Experiment 1. Epinephrine effect on IR2G 
 Epinephrine is a potent adrenergic ligand that binds to a wide spectrum of both α- and β-
adrenergic receptors in the body. As mentioned previously, Earl et al [11] reported that EPI 
treatment before the injection of insulin in horses resulted in a total obliteration of the expected 
decrease in blood glucose concentrations relative to saline-treated horses. Moreover, blood 
glucose concentrations actually increased in EPI-treated animals. The interference of EPI with 
insulin action on insulin sensitive tissues has been reported for various species [71-73], and it is 
thought that EPI inhibits insulin-stimulated glucose uptake in skeletal muscle by first stimulating 
intramuscular glycogenolysis, resulting in high glucose-6-phosphate concentrations that then 
inhibit glucose phosphorylation [72,73]. It has also been reported that EPI raises blood glucose 
concentrations via stimulation of glycogenolysis in the liver [74] as well as skeletal muscle [73].  
 The inhibitory effect of EPI treatment on IR2G presented herein has not been reported 
previously for horses, although similar effects have been reported for other species [75-77]. The 
use of specific α- versus β-adrenergic agonists has shown that the inhibition of insulin secretion 
is primarily mediated through α-adrenergic receptors, and in fact, pure β-adrenergic agonists 
often cause stimulation of insulin secretion, rather than inhibition [77]. Thus, it is assumed that 
the inhibitory effect of EPI on both resting (unstimulated) and glucose-stimulated insulin 
secretion in the mares in the present experiment was due to the ability of EPI to bind to α-
adrenergic receptors, and that binding dominated over any possible effect through β-adrenergic 
receptors that might have occurred at the same time. 
 The present experiment and that of Earl et al [11] both tested an EPI treatment dose of 5 
µg/kg BW on IR2G and GR2I test results. This dose of EPI administered intravenously causes 
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most horses to sweat within a few minutes and produces minor muscle tremor; its effects are 
usually short-lived, with recovery occurring within 10 to 15 minutes after injection. How the 
effects of this dose of EPI compares to those after the acute endogenous release of EPI in 
response to any given level of stress in horses is unknown. Estimations of the change (rise) in 
EPI concentrations per se from reports on horses exposed to treadmill exercise (at high Vmax or 
at exhaustion) vary from 1.35 [78] to 6 [79] to 68.2 [80] nmol/L; the equivalent net (greatest) 
change after administration of EPI at 5 µg/kg BW intravenously to a 500 kg horse would be 
approximately 450 nmol/L. Thus, further research is needed to determine the relative minimal 
dose of exogenous EPI that would alter the various physiologic systems affected (e.g., heart rate, 
liver glycogenolysis, perturbation of insulin secretion, etc.). 
5.2  Experiments 2, 3, and 4. Detomidine and Butorphanol effects on IR2G and GR2I 
 Detomidine at the dosage routinely used to sedate horses was a powerful inhibitor of 
insulin secretion, both before stimulation with glucose, as well as after stimulation. Addition of 
BUT did not further alter that response, and BUT alone (Experiment 3) had no effect on insulin 
concentrations. Detomidine is known to be a potent α-adrenergic agonist with apparently little or 
no β-adrenergic activity [53]. The lack of β-adrenergic activity was in fact confirmed by the 
results of Experiment 3: the lack of effect of DET on GR2I is in stark contrast to the EPI effect 
on GR2I reported by Earl et al [11]. Both of these results are consistent with what has been 
reported for other species. That is, α-adrenergic agonists consistently suppress insulin secretion 
from the pancreas and from isolated pancreatic islets [53,81] whereas β-adrenergic agents often 
stimulate insulin secretion in the absence of α-adrenergic activity [77,82]. In contrast, β-
adrenergic agonists block the action of insulin in insulin-sensitive tissues primarily by blocking 
the phosphorylation of glucose to glucose-6-phosphate [71], thus eliminating the needed 
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concentration gradient for glucose transport between the extracellular fluid and intracellular 
cytoplasm. This suppressive effect of β-adrenergic agonists on glucose uptake is not produced by 
α-adrenergic agonists [82,83; results from Experiment 3]. 
 Given the suppressive effect of DET and DET/BUT on IR2G, neither approach to 
sedation would be useful for assessing insulin sensitivity in horses. However, the lack of effect 
of DET on the GR2I indicates that this option should be useful for testing fractious horses. The 
tendency of the lesser response in DET/BUT treated mares may indicate an interaction between 
the two drugs on GR2I, which would need to be confirmed or rebutted in future experiments. 
 In conclusion, of the two commonly used assessments of insulin sensitivity in horses, the 
GR2I and the IR2G, the IR2G is profoundly affected by both EPI and DET, presumably through 
the α-adrenergic receptor stimulation. In contrast, the GR2I, previously shown to be severely 
altered by EPI administration [11], was not affected by DET/BUT sedation. This indicates that 
this drug combination should be useful for sedating fractious horses for the assessment of insulin 
sensitivity by this method [10]. 
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CHAPTER 6. SUMMARY AND CONCLUSIONS 
The results from Experiment 1 confirmed that epinephrine administration not only 
inhibits the insulin-induced uptake of glucose in horses, but interferes with the normal glucose-
induced release of insulin from the pancreas. Experiment 2 indicated that the commonly used α-
adrenergic sedative, detomidine, completely precluded the expected insulin response to glucose 
infusion; that effect was not altered by combining the opioid agonist, butorphanol, with 
detomidine. In contrast, the combination of the two drugs for sedation had no effect on the 
expected decrease in blood glucose after insulin administration (Experiment 3); the observed 
tendency of detomidine to reduce insulin’s effect was tenuous and needs further study. Finally, 
Experiment 4 indicated that butorphanol alone administered to horses did not alter the insulin 
response to infused glucose. 
Taken together, these data indicate that sedation with detomidine, and likely other α-
adrenergic agonists, cannot be used to assess the insulin response to glucose as an assessment of 
insulin resistance. The combination of detomidine and butorphanol does appear to be a viable 
alternative for the sedation of horses for measurement of the insulin-induced decrease in blood 
glucose, which is a proven method of assessing insensitivity in horses. 
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